Moderna, Inc. (MRNA)

80.32 +0.37 (+0.46%) At close: 04:00PM EST

Moderna, Inc.

200 Technology Square
Cambridge, MA 02139
United States
617 714 6500
https://www.modernatx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 3,900

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Stephane Bancel	CEO & Director	4.97M	392.58M	1973
Dr. Stephen Hoge M.D.	President	2.41M	56.52M	1976
Mr. James M. Mock	Chief Financial Officer	1.49M	N/A	1977
Ms. Arpa Garay	Chief Commercial Officer	2.67M	N/A	1979
Dr. Jerh Collins Ph.D.	Chief Technical Operations & Quality Officer	N/A	N/A	1966
Dr. Melissa J. Moore Ph.D.	Chief Scientific Officer & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Brad Miller	Chief Information Officer	N/A	N/A	1973
Ms. Lavina Talukdar CFA	Senior VP & Head of Investor Relations	N/A	N/A	N/A
Ms. Shannon Thyme Klinger	Chief Legal Officer & Corporate Secretary	1.76M	N/A	1971
Colleen Hussey	Senior Director of Corporate Communications	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a strategic partnership with Caris Life Sciences to advance mRNA-Based oncology therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Moderna, Inc.’s ISS governance QualityScore as of 1 December 2023 is 10. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.